However, therapeutic targeting of TGF-β1 or its receptors did not slow progression of nephropathy in clinical trials [12], and also failed to reduce pulmonary fibrosis in a mouse model, while exacerbating inflammation associated with disease progression [11]. Here, TGFB1 is linked to Nephropathy.